The tentative evidence surrounding alpha-adrenoceptor blockers and their dichotomous impact on conditions like dorsalgia and migraines, along with renin inhibitors’ potential protective effect against dorsalgianas, underscores the complex interplay between cardiovascular pharmacology and pain modulation. The gene discussed is REN; the disease is migraine disorder.